COMMUNIQUÉS West-GlobeNewswire

Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
19/10/2026
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum. [...]
RAMSAY GENERALE DE SANTE : Evolution de la gouvernance - Mise à disposition du DEU 2026 - Assemblée Générale du 4 décembre 2026
19/10/2026
COMMUNIQUÉ DE PRESSE Paris, le 19 octobre 2026 EVOLUTION DE LA GOUVERNANCE DE RAMSAY GENERALE DE SANTE MISE À DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL 2026 ASSEMBLEE GENERALE DU 4 DECEMBRE 2026 Il est rappelé [...]
RAMSAY GENERALE DE SANTE : Availability of the 2026 URD - Evolution in the Governance - Annual General meeting on 4th December 2026
19/10/2026
PRESS RELEASE Paris, 19 October 2026 EVOLUTION IN THE GOVERNANCE OF RAMSAY GENERALE DE SANTE AVAILABILITY OF THE 2026 UNIVERSAL REGISTRATION DOCUMENT ANNUAL GENERAL MEETING ON 4 DECEMBER 2026 Ramsay Health Care Limited [...]
Intelligent Scopes Unveils the ISC 100: The Solution Enabling Urology AI to Work Beside Any Cystoscopy Tower — No Replacement, No Rewiring, No Cloud
19/10/2026
Compact edge platform brings ISC’s AI software to the point of care on NVIDIA Jetson; first software device, CystoSmart™, cleared in Brazil and Singapore ISC 100 by Intelligent Scopes Corp CystoSmart running on the ISC [...]
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
19/10/2026
Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy Data to be presented as a rapid oral presentation at ESMO Congress 2026 on [...]
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
19/10/2026
Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology- [...]
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
18/10/2026
WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
18/10/2026
WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology [...]
TransCon® CNP (navepegritide), administré une fois par semaine, reçoit un avis favorable du CHMP dans le traitement de l’achondroplasie chez l’enfant
17/10/2026
La décision finale de la Commission européenne est attendue au quatrième trimestre 2026 COPENHAGUE, Danemark, 17 oct. 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq : ASND) a annoncé aujourd’hui que le Comité des [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16/10/2026
BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
16/10/2026
WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the [...]
4DMT Announces New Employment Inducement Grants
16/10/2026
EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Nanox Provides Business Update and Furnishes Certain Preliminary Unaudited Financial Data for Third Quarter Ended September 30, 2026
16/10/2026
PETACH TIKVA, Israel, Oct. 16, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an innovative medical imaging technology company, today provided a brief business update and [...]
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/10/2026
CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA ® ) platform to [...]
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/10/2026
WALTHAM, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
HealthRecon Connect Strengthens Compliance with Expanded ISO Certification Scope
16/10/2026
SOUTHLAKE, Texas, Oct. 16, 2026 (GLOBE NEWSWIRE) -- HealthRecon Connect, a technology-enabled Revenue Cycle Management solutions provider to U.S. healthcare organizations, today announced the successful completion of [...]
Kane Biotech Announces $250,000 Insider Loan
16/10/2026
Unsecured, non-interest-bearing loan provides additional working capital support WINNIPEG, Manitoba, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
16/10/2026
PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor [...]
Avicanna Transitions US Listing to OTCQB
16/10/2026
TORONTO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ) (TSX: AVCN) (OTCQB: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of [...]

Pages